Literature DB >> 20977353

The association between primary antiretroviral resistance and HAART virologic failure in a developing set.

Luiz Henrique Gagliani1, Wagner T Alkmim Maia, Dercy Sá-Filho, Luiz Mario Janini, Maria Cecilia Sucupira, Marcos Montani Caseiro, Ricardo Sobhie Diaz.   

Abstract

Santos is a Brazilian port city with high HIV incidence, high primary antiretroviral resistance levels, high HIV-1 BF recombinants prevalence, and high rates of antiretroviral virologic failure. We evaluated factors related to virologic failure after 48 weeks of HAART in this population. We compared demographic and HIV profiles among 43 individuals with virologic failure (group 1) and 37 with virologic success (group 2) after 48 weeks of HAART initiation. The overall primary antiretroviral resistance prevalence was 31.2%; 46.5% in group 1 and 13.5% in group 2 (p < 0.005). Nine patients from group 1 and seven from group 2 were infected by F or BF strains. Fifteen individuals presented with NRTI mutations, 13 with NNRTI mutations, three with PI mutations, and five with NRTI and NNRTI mutations. No significant differences were observed in baseline viral load, CD4, clade assignment, antiretrovirals used, or demographics among groups or patients harboring resistant versus wild-type viruses. In this region, there was a high prevalence of antiretroviral resistance among long standing infected patients whose disease had progressed. This finding supports the concept that resistance testing prior to ART initiation is cost effective. The association between primary antiretroviral resistance and virologic failure may suggest that primary resistance greatly impairs antiretroviral activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977353     DOI: 10.1089/aid.2010.0150

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.

Authors:  Michael Murphey-Corb; Premeela Rajakumar; Heather Michael; Julia Nyaundi; Peter J Didier; Aaron B Reeve; Hiroaki Mitsuya; Stefan G Sarafianos; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2012-06-19       Impact factor: 5.191

2.  Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.

Authors:  Sasisopin Kiertiburanakul; Romanee Chaiwarith; Sunee Sirivichayakul; Rossana Ditangco; Awachana Jiamsakul; Patrick C K Li; Pacharee Kantipong; Christopher Lee; Winai Ratanasuwan; Adeeba Kamarulzaman; Annette H Sohn; Somnuek Sungkanuparph
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

3.  Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil--1996-2012.

Authors:  Unaí Tupinambás; Helena Duani; Ana Virgínia Cunha Martins; Agdemir Waleria Aleixo; Dirceu Bartolomeu Greco
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-06       Impact factor: 2.743

4.  Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.

Authors:  Monica B Arruda; Lídia T Boullosa; Cynthia C Cardoso; Carolina M da Costa; Carlos Rb Alves; Shirlene Ts de Lima; Helena T Kaminski; Agdemir W Aleixo; Ana Op Esposito; Ana Ms Cavalcanti; Maristela Riedel; José C Couto-Fernandez; Selma B Ferreira; Ivi Cm de Oliveira; Loreci E Portal; Hilda Hc Wolf; Sandra B Fernandes; Maria I de M C Pardini; Manoel Vc Feiteiro; Fernanda M Tolentino; Ricardo S Diaz; Giselle Isl Lopes; Roberta Bl Francisco; Nazle Mc Véras; Ana F Pires; Miriam Franchini; Fábio Mesquita; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

5.  Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots.

Authors:  Celina M P de Moraes Soares; Tania R C Vergara; Carlos Brites; Jose D U Brito; Gorki Grinberg; Marcos M Caseiro; Carlos Correa; Theodoro A Suffert; Flavio R Pereira; Michelle Camargo; Luiz M Janini; Shirley Komninakis; Maria C A Sucupira; Ricardo S Diaz
Journal:  J Int AIDS Soc       Date:  2014-09-22       Impact factor: 5.396

6.  Extensive variation in drug-resistance mutational profile of Brazilian patients failing antiretroviral therapy in five large Brazilian cities.

Authors:  Carlos Brites; Lauro Pinto-Neto; Melissa Medeiros; Estevão Nunes; Eduardo Sprinz; Mariana Carvalho
Journal:  Braz J Infect Dis       Date:  2016-06-09       Impact factor: 3.257

Review 7.  HIV-1 genetic diversity and drug resistance mutations in the northern Brazilian region.

Authors:  Myuki Alfaia Esashika Crispim; Monica Nogueira da Guarda Reis; Mariane Martins de Araujo Stefani
Journal:  Braz J Infect Dis       Date:  2021-07-13       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.